AU2004267044B8 - Compounds, methods and formulations for the oral delivery of a glucagon like peptide (GLP)-1 compound or an melanocortin 4 receptor (MC4) agonist peptide - Google Patents
Compounds, methods and formulations for the oral delivery of a glucagon like peptide (GLP)-1 compound or an melanocortin 4 receptor (MC4) agonist peptide Download PDFInfo
- Publication number
- AU2004267044B8 AU2004267044B8 AU2004267044A AU2004267044A AU2004267044B8 AU 2004267044 B8 AU2004267044 B8 AU 2004267044B8 AU 2004267044 A AU2004267044 A AU 2004267044A AU 2004267044 A AU2004267044 A AU 2004267044A AU 2004267044 B8 AU2004267044 B8 AU 2004267044B8
- Authority
- AU
- Australia
- Prior art keywords
- compound
- glp
- alkyl
- peptide
- pharmaceutical salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49653703P | 2003-08-20 | 2003-08-20 | |
| US60/496,537 | 2003-08-20 | ||
| PCT/US2004/024387 WO2005019212A1 (en) | 2003-08-20 | 2004-08-18 | Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2004267044A1 AU2004267044A1 (en) | 2005-03-03 |
| AU2004267044B2 AU2004267044B2 (en) | 2009-12-03 |
| AU2004267044B8 true AU2004267044B8 (en) | 2009-12-17 |
Family
ID=34216017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2004267044A Ceased AU2004267044B8 (en) | 2003-08-20 | 2004-08-18 | Compounds, methods and formulations for the oral delivery of a glucagon like peptide (GLP)-1 compound or an melanocortin 4 receptor (MC4) agonist peptide |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20070293423A1 (enExample) |
| EP (1) | EP1658285B1 (enExample) |
| JP (2) | JP4754487B2 (enExample) |
| CN (1) | CN100398536C (enExample) |
| AT (1) | ATE361294T1 (enExample) |
| AU (1) | AU2004267044B8 (enExample) |
| BR (1) | BRPI0413676B8 (enExample) |
| CA (1) | CA2530983C (enExample) |
| DE (1) | DE602004006279T2 (enExample) |
| ES (1) | ES2286679T3 (enExample) |
| MX (1) | MXPA06001916A (enExample) |
| WO (1) | WO2005019212A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006269321A1 (en) | 2005-07-08 | 2007-01-18 | Ipsen Pharma S.A.S. | Ligands of melanocortin receptors |
| HUE037147T2 (hu) | 2005-07-08 | 2018-08-28 | Ipsen Pharma | Melanokortin-receptor ligandumai |
| WO2008027958A2 (en) * | 2006-08-31 | 2008-03-06 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| CA2689016C (en) * | 2007-05-25 | 2014-08-12 | Ipsen Pharma S.A.S. | Melanocortin receptor ligands modified with hydantoin |
| BRPI0909947A2 (pt) | 2008-06-09 | 2017-06-27 | Palatin Technologies Inc | '' peptídeo cíclico, composição farmacêutica, método de tratamento de uma doença, indicação, condição ou síndrome mediada por receptor de melanocortina em seres humanos ou mamíferos não humanos, e, método de tratamento de condição que reage a alterações da função de receptor de melanocortina em seres humanos ou mamíferos não humanos'' |
| CN102458436B (zh) | 2009-06-08 | 2015-06-03 | 帕拉丁科技公司 | 黑皮质素受体特异性肽 |
| UY32690A (es) | 2009-06-08 | 2011-01-31 | Astrazeneca Ab | Péptidos específicos para receptores de melanocortina |
| EP2440572B1 (en) | 2009-06-08 | 2017-04-05 | Palatin Technologies, Inc. | Lactam-bridged melanocortin receptor-specific peptides |
| BR112012011780A2 (pt) | 2009-11-23 | 2019-09-24 | Palatin Technologies, Inc | peptídeo linear,composição farmacêutica,métodopara tratamento de umadoença,indicação,condição ou sídrome mediadsa por receptor de melanocortina emum mamífero humano ou não humano e método para tratamento de uma condição responsiva ás alterações em função de receptor de melanocortina em um mamifero humano ou não humano |
| MX2012005862A (es) | 2009-11-23 | 2012-09-07 | Palatin Technologies Inc | Peptidos ciclicos especificos del receptor de melanocortina-1. |
| US10357348B2 (en) * | 2013-08-19 | 2019-07-23 | Warren Matthew Leevy | Fluid manifold |
| US20160244860A1 (en) * | 2015-02-20 | 2016-08-25 | Cytec Industries Inc. | Aliphatic-aromatic heterocyclic compounds and uses thereof in metal extractant compositions |
| WO2016168388A2 (en) | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
| CN105017136A (zh) * | 2015-07-24 | 2015-11-04 | 陈吉美 | 一种2-溴-3-甲氧基吡啶的制备方法 |
| BR112019016241A2 (pt) | 2017-02-08 | 2020-04-07 | Bayer Cropscience Ag | derivados de triazol e seu uso como fungicidas |
| EP3580218A1 (en) | 2017-02-08 | 2019-12-18 | Bayer CropScience Aktiengesellschaft | Novel triazole derivatives |
| CN110267952A (zh) | 2017-02-08 | 2019-09-20 | 拜耳公司 | 三唑硫酮衍生物 |
| AU2018217749A1 (en) | 2017-02-10 | 2019-08-01 | Bayer Aktiengesellschaft | Composition for controlling harmful microorganisms comprising 1 -(phenoxy-pyridinyl)-2-(1,2,4-triazol-1 -yl)-ethanol derivatives |
| WO2020020816A1 (en) | 2018-07-26 | 2020-01-30 | Bayer Aktiengesellschaft | Novel triazole derivatives |
| CN111793038B (zh) * | 2019-04-08 | 2022-08-12 | 新发药业有限公司 | 一种取代噁唑化合物的环保制备方法 |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2423709A (en) * | 1947-07-08 | X-aryl thiazole | ||
| WO2000047188A1 (en) * | 1999-02-11 | 2000-08-17 | Emisphere Technologies, Inc. | Oxadiazole compounds and compositions for delivering active agents |
| US6211215B1 (en) * | 1996-07-19 | 2001-04-03 | Takeda Chemical Industries, Ltd. | Heterocyclic compounds, their production and use |
| US6294580B1 (en) * | 1996-02-28 | 2001-09-25 | Glaxo Wellcome Inc. | Substituted 4-hydroxy-phenylalcanoic acid derivatives with agonist activity to PPAR-gamma |
| WO2002016331A1 (en) * | 2000-08-23 | 2002-02-28 | Eli Lilly And Company | Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists |
| WO2002018355A1 (en) * | 2000-08-23 | 2002-03-07 | Eli Lilly And Company | Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists |
| WO2002040458A1 (en) * | 2000-11-17 | 2002-05-23 | Takeda Chemical Industries, Ltd. | Isoxazole derivatives |
| WO2002050091A1 (en) * | 2000-12-21 | 2002-06-27 | Glaxo Group Limited | Macrolide antibiotics |
| WO2003015785A1 (en) * | 2001-08-15 | 2003-02-27 | Icos Corporation | 2h-phthalazin-1-ones and methods for use thereof |
| US6605629B1 (en) * | 1999-08-25 | 2003-08-12 | Takeda Chemical Industries, Ltd. | Neurotrophin production secretion promoting agent |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US595503A (en) * | 1897-12-14 | Cross-clevis | ||
| US3412193A (en) * | 1965-12-13 | 1968-11-19 | American Cyanamid Co | 11-(4-methyl-1-piperazinyl)dibenz[b, f][1, 4]oxazepines or thiazepines for controlling fertility |
| US3578671A (en) * | 1967-11-06 | 1971-05-11 | Wyeth John & Brother Ltd | Oxazoles |
| FR2374910A1 (fr) * | 1976-10-23 | 1978-07-21 | Choay Sa | Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations |
| AU610083B2 (en) * | 1986-08-18 | 1991-05-16 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents |
| EP0451790A1 (de) * | 1990-04-12 | 1991-10-16 | Hoechst Aktiengesellschaft | 3,5-disubstituierte 2-Isoxazoline und Isoxazole, Verfahren zu deren Herstellung, diese enthaltende Mittel und ihre Verwendung |
| US5541155A (en) * | 1994-04-22 | 1996-07-30 | Emisphere Technologies, Inc. | Acids and acid salts and their use in delivery systems |
| US5693338A (en) * | 1994-09-29 | 1997-12-02 | Emisphere Technologies, Inc. | Diketopiperazine-based delivery systems |
| US5643957A (en) * | 1993-04-22 | 1997-07-01 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US6001347A (en) * | 1995-03-31 | 1999-12-14 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5650386A (en) * | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
| BR9604880A (pt) * | 1995-03-31 | 1998-05-19 | Emisphere Tech Inc | Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica |
| US5989539A (en) * | 1995-03-31 | 1999-11-23 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5965121A (en) * | 1995-03-31 | 1999-10-12 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5866536A (en) * | 1995-03-31 | 1999-02-02 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5820881A (en) * | 1995-04-28 | 1998-10-13 | Emisphere Technologies, Inc. | Microspheres of diamide-dicarboxylic acids |
| JP4056589B2 (ja) * | 1996-07-19 | 2008-03-05 | 武田薬品工業株式会社 | 複素環化合物、その製造法および用途 |
| DK1093819T3 (da) * | 1997-02-07 | 2006-09-11 | Emisphere Tech Inc | Forbindelse og præparat til tilförsel af aktive midler |
| US6313088B1 (en) * | 1997-02-07 | 2001-11-06 | Emisphere Technologies, Inc. | 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents |
| CN1338924A (zh) | 1999-01-08 | 2002-03-06 | 艾米斯菲尔技术有限公司 | 聚合物输送剂和输送剂化合物 |
| WO2000050386A1 (en) | 1999-02-26 | 2000-08-31 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| JP4588221B2 (ja) | 1999-04-05 | 2010-11-24 | エミスフェアー・テクノロジーズ・インク | 活性剤を送達するための二ナトリウム塩、一水和物、およびエタノール溶媒和物 |
| SE9902987D0 (sv) * | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
| CZ20021570A3 (cs) | 1999-11-05 | 2002-10-16 | Emisphere Technologies, Inc. | Fenylaminkarboxylové kyseliny a kompozice pro dodávání aktivních činidel |
| ES2298168T3 (es) | 1999-12-16 | 2008-05-16 | Emisphere Technologies, Inc. | Compuestos y composiciones para suministrar agentes activos. |
| EP1246792B1 (en) | 2000-01-13 | 2014-08-13 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| PT1299348E (pt) | 2000-06-29 | 2008-05-12 | Emisphere Tech Inc | Compostos e composições para administração de agentes activos |
| JP4148672B2 (ja) * | 2000-11-17 | 2008-09-10 | 武田薬品工業株式会社 | イソオキサゾール誘導体 |
| JP4248244B2 (ja) * | 2001-02-14 | 2009-04-02 | 明治製菓株式会社 | １２、１３位変換新規１６員環マクロライド誘導体 |
| GB2373186A (en) * | 2001-02-23 | 2002-09-18 | Astrazeneca Ab | Pharmaceutical combinations of a CCR3 antagonist and a compound which is usefulreatment of asthma, allergic disease or inflammation |
| AU2002305720A1 (en) * | 2001-05-30 | 2002-12-09 | Huening, Tracy, T. | Piperazine pentanamide hiv protease inhibitors |
| US6969057B2 (en) | 2001-10-30 | 2005-11-29 | Illinois Tool Works Inc. | Method and apparatus for adjusting and positioning air caps |
| AU2002367426A1 (en) * | 2001-12-28 | 2003-07-24 | Takeda Chemical Industries, Ltd. | Neurotrophic factor production/secretion accelerator |
| US20050148497A1 (en) | 2002-02-20 | 2005-07-07 | Khan Mohammed A. | Method for administering glp-1 molecules |
| CA2487315A1 (en) * | 2002-05-24 | 2003-12-04 | Takeda Pharmaceutical Company Limited | 1,2-azole derivatives with hypoglycemic and hypolipidemic activity |
| JP2004277397A (ja) * | 2002-05-24 | 2004-10-07 | Takeda Chem Ind Ltd | １，２−アゾール誘導体 |
| WO2005000339A2 (en) | 2003-06-19 | 2005-01-06 | Eli Lilly And Company | Melanocortin receptor 4(mc4) agonists and their uses |
| WO2005019184A1 (en) * | 2003-08-20 | 2005-03-03 | Eli Lilly And Company | Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide |
-
2004
- 2004-08-18 ES ES04779447T patent/ES2286679T3/es not_active Expired - Lifetime
- 2004-08-18 JP JP2006523866A patent/JP4754487B2/ja not_active Expired - Fee Related
- 2004-08-18 AT AT04779447T patent/ATE361294T1/de not_active IP Right Cessation
- 2004-08-18 US US10/566,012 patent/US20070293423A1/en not_active Abandoned
- 2004-08-18 CN CNB2004800227912A patent/CN100398536C/zh not_active Expired - Fee Related
- 2004-08-18 EP EP04779447A patent/EP1658285B1/en not_active Expired - Lifetime
- 2004-08-18 DE DE602004006279T patent/DE602004006279T2/de not_active Expired - Lifetime
- 2004-08-18 BR BRPI0413676A patent/BRPI0413676B8/pt not_active IP Right Cessation
- 2004-08-18 CA CA2530983A patent/CA2530983C/en not_active Expired - Fee Related
- 2004-08-18 AU AU2004267044A patent/AU2004267044B8/en not_active Ceased
- 2004-08-18 WO PCT/US2004/024387 patent/WO2005019212A1/en not_active Ceased
- 2004-08-18 MX MXPA06001916A patent/MXPA06001916A/es active IP Right Grant
-
2008
- 2008-11-03 US US12/263,722 patent/US7947841B2/en not_active Expired - Fee Related
-
2011
- 2011-04-14 US US13/087,255 patent/US8546581B2/en not_active Expired - Fee Related
- 2011-05-09 JP JP2011104435A patent/JP2011207886A/ja active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2423709A (en) * | 1947-07-08 | X-aryl thiazole | ||
| US6294580B1 (en) * | 1996-02-28 | 2001-09-25 | Glaxo Wellcome Inc. | Substituted 4-hydroxy-phenylalcanoic acid derivatives with agonist activity to PPAR-gamma |
| US6211215B1 (en) * | 1996-07-19 | 2001-04-03 | Takeda Chemical Industries, Ltd. | Heterocyclic compounds, their production and use |
| WO2000047188A1 (en) * | 1999-02-11 | 2000-08-17 | Emisphere Technologies, Inc. | Oxadiazole compounds and compositions for delivering active agents |
| US6605629B1 (en) * | 1999-08-25 | 2003-08-12 | Takeda Chemical Industries, Ltd. | Neurotrophin production secretion promoting agent |
| WO2002016331A1 (en) * | 2000-08-23 | 2002-02-28 | Eli Lilly And Company | Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists |
| WO2002018355A1 (en) * | 2000-08-23 | 2002-03-07 | Eli Lilly And Company | Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists |
| WO2002040458A1 (en) * | 2000-11-17 | 2002-05-23 | Takeda Chemical Industries, Ltd. | Isoxazole derivatives |
| WO2002050091A1 (en) * | 2000-12-21 | 2002-06-27 | Glaxo Group Limited | Macrolide antibiotics |
| WO2003015785A1 (en) * | 2001-08-15 | 2003-02-27 | Icos Corporation | 2h-phthalazin-1-ones and methods for use thereof |
Non-Patent Citations (2)
| Title |
|---|
| Het Com, 2001, 7(5): 411-416 * |
| J Med Chem, 1988, 31(6): 1197-1204 * |
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0413676A (pt) | 2006-10-24 |
| US20110190205A1 (en) | 2011-08-04 |
| CA2530983A1 (en) | 2005-03-03 |
| WO2005019212A1 (en) | 2005-03-03 |
| BRPI0413676B1 (pt) | 2018-07-24 |
| US8546581B2 (en) | 2013-10-01 |
| US20090239798A1 (en) | 2009-09-24 |
| DE602004006279T2 (de) | 2007-12-27 |
| BRPI0413676B8 (pt) | 2021-05-25 |
| US7947841B2 (en) | 2011-05-24 |
| EP1658285B1 (en) | 2007-05-02 |
| ES2286679T3 (es) | 2007-12-01 |
| JP2011207886A (ja) | 2011-10-20 |
| DE602004006279D1 (de) | 2007-06-14 |
| CN100398536C (zh) | 2008-07-02 |
| ATE361294T1 (de) | 2007-05-15 |
| JP4754487B2 (ja) | 2011-08-24 |
| CN1832944A (zh) | 2006-09-13 |
| JP2007502817A (ja) | 2007-02-15 |
| CA2530983C (en) | 2012-09-25 |
| MXPA06001916A (es) | 2006-05-17 |
| US20070293423A1 (en) | 2007-12-20 |
| EP1658285A1 (en) | 2006-05-24 |
| AU2004267044A1 (en) | 2005-03-03 |
| AU2004267044B2 (en) | 2009-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7947841B2 (en) | Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP)-1 compound or a melanocortin-4 receptor (MC4) agonist peptide | |
| US8765796B2 (en) | Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP-1) compound or a melanocortin-4 receptor (MC4) agonist peptide | |
| JP6101326B2 (ja) | 規定された含量の異性体を有するジケトピペラジン微粒子 | |
| US20080318958A1 (en) | New utilities of tricyclic compounds | |
| KR20110059723A (ko) | 세포내 칼슘을 조절하는 화합물 | |
| CN1253553A (zh) | 取代的苯基衍生物、其制备方法以及用途 | |
| CN101528717A (zh) | 噻唑和唑-取代的芳基酰胺类化合物 | |
| US9051265B2 (en) | N-benzylindole modulators of PPARG | |
| US20100274022A1 (en) | G protein-coupled receptor inhibitor and pharmaceutical product | |
| US10266490B2 (en) | Radioprotector compounds | |
| WO2005023803A1 (en) | Phosphoric acid salt of 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl] methyl]- 2,4-thiazolidinedione | |
| JPH1045592A (ja) | 糖尿病合併症治療剤 | |
| WO2003050097A1 (en) | Sodium salt of benzyl thiazolidine-2,4-dione derivative and hydrate thereof | |
| WO2005021543A1 (en) | Phosphoric acid salt of 5-[[4-[2-(5-ethyl-2-pyridinyl) ethoxy] phenyl] methyl]-2, 4-thiazolidinedione |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: EMISPHERE TECHNOLOGIES, INC. Free format text: FORMER APPLICANT(S): ELI LILLY AND COMPANY |
|
| TH | Corrigenda |
Free format text: IN VOL 23, NO 47, PAGE(S) 11335 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME EMISPHERE TECHNOLOGIES, INC., APPLICATION NO. 2004267044, UNDER INID (72), CORRECT THE CO-INVENTOR TO MCGILL III, JOHN MCNEILL |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |